178261-85-3

Upstream product

• 6068-72-0 4-cyanobenzoyl chlorIde 
• 188350-66-5 ethyl 6-aminochroman-3-acetate 
• 6065-32-3 4-bromocrotonic ethyl ester 
• 1761-61-1 5-bromosalicyclaldehyde 
• 478064-32-3 C₁₃H₁₃BrO₄ 
• 3034-34-2 4-cyanobenzamide 
• 1432752-93-6 C₁₃H₁₅BrO₃ 
• 68043-53-8 6-nitrochroman-4-one 

Downstream Products

• 1432753-22-4 C₂₃H₂₆N₂O₅*ClH 

Relevant academic research and scientific papers

PPh3-mediated intramolecular conjugation of alkyl halides with electron-deficient olefins: Facile synthesis of chromans and relevant analogues

With the mediation of phosphine, the direct intramolecular coupling of two electrophiles-alkyl halides with electron-deficient olefins-has been successfully realized in an intramolecular conjugate addition manner. The reaction provides a new approach for

New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: Orally active series of N-alkylated amidines with a 6,6-bicyclic template

The design, synthesis, and pharmacological evaluation of (S)-(-)-ethyl [6-[4-(morpholino-formimidoyl)benzamido]-3,4-dihydro-2H-1-benzopyran-3- yl]acetate hydrochloride ((S)-4·HCl, MS-180), an orally active glycoprotein IIb-IIIa (GPIIb-IIIa) antagonist, are reported. Pharmacophore mapping of amidino and carboxyl groups of already known GPIIb-IIIa antagonists led to the synthesis of nine amidino acids containing 6,6-bicyclic ring skeletons (10a-i). Among them, the compounds 10a,c,e having an amide bond and 1,2,3,4- tetrahydronaphthalene or 3,4-dihydro-2H-1-benzopyran skeleton showed marked inhibitions with IC50 values of 46-57 nM in human platelet aggregation assay in vitro, but low oral activities. N-Alkylation of the amidino group coupled with the ester prodrug approach afforded MS-180 ((S)-4·HCl), which generates in vivo the corresponding carboxylic acid (S)-3 as an active species. In vitro, (S)-3 inhibited ADP-induced aggregation of guinea pig, dog, and human platelets (IC50 = 110, 253, and 35 nM, respectively) and inhibited the binding of fibrinogen to immobilized GPIIb-IIIa of human platelets (IC50 = 0.12 nM). After oral administration of MS-180 ((S)4·HCl) to fasted beagle dog, ex vivo inhibition of platelet aggregation was observed. The maximal inhibitions were observed 2-4 h after dosing with dose dependency (60% inhibition at a dose of 1 mg/kg, 85% at 3 mg/kg, and 100% at 10 mg/kg, respectively) and the extent of the inhibitions paralleled the plasma concentration of the active species (S)-3. On the basis of these studies, we selected MS-180 ((S)-4·HCl) as a candidate for clinical evaluation as a drug for the treatment and prevention of thrombosis in patients.

Amidine derivatives and platelet aggregation inhibitor containing the same

The invention relates to a substituted amidine derivative which has an excellent platelet aggregation inhibiting action on the basis of fibrinogen antagonism and is particularly excellent in effectiveness on oral administration, and the platelet aggregati

Bicyclic compound and platelet aggregation inhibitor containing the same

The invention relates to a novel compound which is represented by the formula (1) and has an excellent platelet aggregation inhibiting action based on fibrinogen antagonism. The platelet aggregation inhibitor containing the compound of the formula (1) as an effective ingredient are effective for prevention and curing of thrombosis and restenosis or reocclusion after percutaneous transluminal coronary angioplasty or percutaneous transluminal coronary recanalization.

Amidine derivatives and platelet aggregation inhibitor containing the same

The invention relates to a substituted amidine derivative which has an excellent platelet aggregation inhibiting action on the basis of fibrinogen antagonism and is particularly excellent in effectiveness on oral administration, and the platelet aggregati